Terns Pharmaceuticals, Inc.

Clinical-stage oncology company developing TERN-701, an oral allosteric BCR::ABL1 TKI for CML. Nasdaq: TERN. HQ: Foster City, CA. Pending acquisition by Merck announced Mar 2026.